The Presidential Daily Brief


  1. dnashutterstock 251435335

    FDA Approves Over-the-Counter Genetic Cancer Test

    This week the FDA approved 23andMe’s $199 home test for mutations linked to breast cancer. The first consumer product of its kind, it targets three specific gene mutations that are most common in people of Ashkenazi Jewish descent: Women with one of them have a 45 to 85 percent chance of developing breast cancer by the age of 70. 23andMe, which hopes to offer tests for other variants soon, warned that its test does not actually diagnose cancer, and the FDA noted that most cancer isn’t caused by hereditary mutations.

This story is part of The Presidential Daily Brief

view full edition